Adding the corneal inlay into a general or refractive surgery practice can be a great benefit to patients and the practice when done correctly.
Photorefractive intrastromal cross-linking is being developed for non-invasive correction of low refractive errors.
Tear osmolarity testing provides clinicians the opportunity to detect disease and select treatments to restore ocular surface health.
Results from the Phase 3 OPUS-3 trial provide evidence confirming a benefit of lifitegrast ophthalmic solution 5.0% (Xiidra, Shire) for significantly improving dry eye disease-related symptoms, as measured by Eye Dryness Score.
Analyses of data from 293 eyes undergoing uncomplicated Descemet membrane endothelial keratoplasty (DMEK) show that endothelial cell loss is greater in eyes that undergo a single re-bubbling for graft separation. The study, however, does not establish a causal association.
Under the best of circumstances—meaning when cataract surgery is performed in an eye with a normal cornea by expert hands and with use of an advanced IOL power calculation formula—the achieved refractive outcome will be more than 0.5 D off target in 1 out of every 11 eyes.
Five-year results from a study of the Boston keratoprosthesis type 1 implant suggest that frozen and fresh corneal donors offer similar clinical outcomes—with no significant differences in device retention, visual rehabilitation or complication rates.
Treating ocular surface disease may have an impact on the effectiveness of glaucoma treatment. Inder Paul Singh, MD, offers some strategies used in practice.
In order to avoid a public health crisis and keep up with increasing vision loss among the aging baby-boomer generation, correctable vision impairments must be eliminated by 2030, according to a report issued by the National Academies of Sciences, Engineering, and Medicine (NASEM).
On the heels of the recent FDA approval of corneal collagen crosslinking, some surgical pearls are provided for the treatment of progressive keratoconus and corneal ectasia.